TECARTUS DIN 02516667
Status: Marketed
Holder: GILEAD SCIENCES CANADA INC
Health Canada record
| Active ingredient(s) | BREXUCABTAGENE AUTOLEUCEL 200000000 CELLS |
|---|
| Dosage form | Suspension |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L01XL06 BREXUCABTAGENE AUTOLEUCEL |
|---|
| Original market date | 16-Dec-2021 |
|---|
| Current status date | 16-Dec-2021 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BREXUCABTAGENE AUTOLEUCEL
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02532719 | TECARTUS | GILEAD SCIENCES CANADA INC | Suspension | BREXUCABTAGENE AUTOLEUCEL 100000000 CELLS | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 35648 | 2025-06-26 | Supplement to a New Drug Submission (SNDS) | Labelling updates |
| 26027 | 2021-06-08 | New Drug Submission (NDS) | |
Request a quote for TECARTUS
How to read a Canadian DIN record